U.S. Markets close in 5 hrs 50 mins
  • S&P 500

    3,906.09
    -19.34 (-0.49%)
     
  • Dow 30

    31,875.78
    -86.08 (-0.27%)
     
  • Nasdaq

    13,486.73
    -111.24 (-0.82%)
     
  • Russell 2000

    2,283.45
    -0.93 (-0.04%)
     
  • Crude Oil

    62.86
    -0.36 (-0.57%)
     
  • Gold

    1,779.40
    -18.50 (-1.03%)
     
  • Silver

    27.83
    -0.03 (-0.10%)
     
  • EUR/USD

    1.2226
    +0.0058 (+0.4768%)
     
  • 10-Yr Bond

    1.4560
    +0.0670 (+4.82%)
     
  • Vix

    22.34
    +1.00 (+4.69%)
     
  • GBP/USD

    1.4152
    +0.0011 (+0.0750%)
     
  • USD/JPY

    106.1580
    +0.2760 (+0.2607%)
     
  • BTC-USD

    51,040.23
    +1,371.98 (+2.76%)
     
  • CMC Crypto 200

    1,020.50
    +25.84 (+2.60%)
     
  • FTSE 100

    6,675.80
    +16.83 (+0.25%)
     
  • Nikkei 225

    30,168.27
    +496.57 (+1.67%)
     

Novo Nordisk A/S: Rectification

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Novo Nordisk A/S
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Bagsværd, Denmark, 7 December 2020 – The Danish Maritime and Commercial High Court has ruled that Novo Nordisk's publication of the press release of 19 September 2019: "Tresiba® showed an overall lower risk of hypoglycaemia and significantly lower HbA1c when compared to insulin glargine U300 in people with type 2 diabetes" was in violation of the Danish Marketing Practices Act and the Danish Medicines Act. Therefore, Novo Nordisk has been ordered to issue this rectification by which Novo Nordisk withdraws the press release of 19 September 2019.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Media:

Charlotte Zarp-Andersson

+45 3079 7603

czpa@novonordisk.com

Attachment